☰

Michael C. Desch - Publications

Affiliations: 
Notre Dame University, South Bend , Indiana,USA 
Area:
International security
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. PMID 36971864 DOI: 10.1007/s00406-023-01576-z  0.518
2023 Desch M, Schlecker C, Hohl K, Liesenfeld KH, Chan T, Müller F, Wunderlich G, Keller S, Ishiguro N, Wind S. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study. Journal of Clinical Psychopharmacology. PMID 36700734 DOI: 10.1097/JCP.0000000000001656  0.506
2022 Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Schölch C, Desch M, Hennige AM. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, Obesity & Metabolism. PMID 36527386 DOI: 10.1111/dom.14948  0.499
2022 Burkard U, Desch M, Shatillo Y, Wunderlich G, Mack SR, Schlecker C, Teitelbaum AM, Liu P, Chan TS. Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [C]‑BI 425809 in Healthy Males. Clinical Drug Investigation. PMID 35286627 DOI: 10.1007/s40261-022-01134-w  0.481
2022 Burkard U, Desch M, Shatillo Y, Wunderlich G, Mack SR, Schlecker C, Teitelbaum AM, Liu P, Chan TS. The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [C]-BI 425809 in Healthy Males. Clinical Drug Investigation. 42: 87-99. PMID 34936055 DOI: 10.1007/s40261-021-01111-9  0.525
2021 Desch M, Wunderlich G, Goettel M, Goetz S, Liesenfeld KH, Chan TS, Rosenbrock H, Sennewald R, Link J, Keller S, Wind S. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics. PMID 34716565 DOI: 10.1007/s13318-021-00723-y  0.532
2021 Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet. Psychiatry. 8: 191-201. PMID 33610228 DOI: 10.1016/S2215-0366(20)30513-7  0.515
2018 Rosenbrock H, Desch M, Kleiner O, Dorner-Ciossek C, Schmid B, Keller S, Schlecker C, Moschetti V, Goetz S, Liesenfeld KH, Fillon G, Giovannini R, Ramael S, Wunderlich G, Wind S. Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. Clinical and Translational Science. PMID 30136756 DOI: 10.1111/cts.12578  0.528
2018 Moschetti V, Schlecker C, Wind S, Goetz S, Schmitt H, Schultz A, Liesenfeld KH, Wunderlich G, Desch M. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics. Clinical Drug Investigation. PMID 29846887 DOI: 10.1007/s40261-018-0660-2  0.548
2017 Moschetti V, Desch M, Goetz S, Liesenfeld KH, Rosenbrock H, Kammerer KP, Wunderlich G, Wind S. Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study. European Journal of Drug Metabolism and Pharmacokinetics. PMID 29076028 DOI: 10.1007/s13318-017-0440-z  0.556
2012 Mayer S, Roeser M, Lachmann P, Ishii S, Suh JM, Harlander S, Desch M, Brunssen C, Morawietz H, Tsai SY, Tsai MJ, Hohenstein B, Hugo C, Todorov VT. Chicken ovalbumin upstream promoter transcription factor II regulates renin gene expression. The Journal of Biological Chemistry. 287: 24483-91. PMID 22645148 DOI: 10.1074/jbc.M111.329474  0.548
2012 Desch M, Hackmayer G, Todorov VT. Identification of ATF2 as a transcriptional regulator of renin gene. Biological Chemistry. 393: 93-100. PMID 22628303 DOI: 10.1515/BC-2011-157  0.506
2011 Desch M, Harlander S, Neubauer B, Gerl M, Germain S, Castrop H, Todorov VT. cAMP target sequences enhCRE and CNRE sense low-salt intake to increase human renin gene expression in vivo. PflüGers Archiv : European Journal of Physiology. 461: 567-77. PMID 21424707 DOI: 10.1007/s00424-011-0956-z  0.502
2010 Desch M, Schubert T, Schreiber A, Mayer S, Friedrich B, Artunc F, Todorov VT. PPARgamma-dependent regulation of adenylate cyclase 6 amplifies the stimulatory effect of cAMP on renin gene expression. Molecular Endocrinology (Baltimore, Md.). 24: 2139-51. PMID 20861226 DOI: 10.1210/me.2010-0134  0.563
2010 Milenkovic VM, Brockmann M, Meyer C, Desch M, Schweda F, Kurtz A, Todorov V, Strauss O. Regulation of the renin expression in the retinal pigment epithelium by systemic stimuli. American Journal of Physiology. Renal Physiology. 299: F396-403. PMID 20519377 DOI: 10.1152/ajprenal.00576.2009  0.455
2010 Desch M, Schreiber A, Schweda F, Madsen K, Friis UG, Weatherford ET, Sigmund CD, Sequeira Lopez ML, Gomez RA, Todorov VT. Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells. Hypertension. 55: 660-6. PMID 20065157 DOI: 10.1161/Hypertensionaha.109.138800  0.528
2008 Todorov VT, Desch M, Schubert T, Kurtz A. The Pal3 promoter sequence is critical for the regulation of human renin gene transcription by peroxisome proliferator-activated receptor-gamma. Endocrinology. 149: 4647-57. PMID 18483152 DOI: 10.1210/en.2008-0127  0.55
2007 Todorov VT, Desch M, Schmitt-Nilson N, Todorova A, Kurtz A. Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression. Hypertension. 50: 939-44. PMID 17785633 DOI: 10.1161/HYPERTENSIONAHA.107.092817  0.547
2007 Hautmann M, Friis UG, Desch M, Todorov V, Castrop H, Segerer F, Otto C, Schütz G, Schweda F. Pituitary adenylate cyclase-activating polypeptide stimulates renin secretion via activation of PAC1 receptors. Journal of the American Society of Nephrology : Jasn. 18: 1150-6. PMID 17360952 DOI: 10.1681/ASN.2006060633  0.483
Show low-probability matches.